Table 2.
Clinicogenomic Characteristics Of The CGP Cohort.
| Characteristic | All Cases N = 125,128 | PPGV+ Cases N = 12,176 | PPGV- Cases N = 112,952 | P-Value (FDR) | |||
|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | ||
| Age At Bx, Median (Q1, Q3) | 66 (58, 74) | 65 (57, 73) | 67 (58, 74) | < 0.001 | |||
| ≤ 50 Years | 14,452 | 11.8% | 1652 | 13.8% | 12,800 | 11.5% | < 0.001 |
| Unknown | 2313 | - | 212 | - | 2101 | - | - |
| Sex | < 0.001 | ||||||
| Female | 64,885 | 51.9% | 6730 | 55.3% | 58,155 | 51.5% | - |
| Male | 60,243 | 48.1% | 5446 | 44.7% | 54,797 | 48.5% | - |
| Predicted Ancestry | < 0.001 | ||||||
| European | 93,844 | 75.1% | 9633 | 79.2% | 84,211 | 74.6% | ‡ |
| African | 14,646 | 11.7% | 1126 | 9.3% | 13,520 | 12.0% | ‡ |
| Admixed American | 11,132 | 8.9% | 943 | 7.8% | 10,189 | 9.0% | ‡ |
| East Asian | 4148 | 3.3% | 360 | 3.0% | 3788 | 3.4% | - |
| South Asian | 1214 | 1.0% | 98 | 0.8% | 1116 | 1.0% | - |
| Unknown | 144 | - | 16 | - | 128 | - | - |
| Tumor Bx Site | < 0.001 | ||||||
| Local | 47,643 | 43.6% | 4860 | 46.2% | 42,783 | 43.3% | ‡ |
| Metastatic | 27,103 | 24.8% | 2976 | 28.3% | 24,127 | 24.4% | ‡ |
| Lymph Node | 8941 | 8.2% | 935 | 8.9% | 8006 | 8.1% | ‡ |
| Peripheral Blood | 25,584 | 23.4% | 1739 | 16.5% | 23,845 | 24.1% | ‡ |
| Unspecified | 15,857 | - | 1666 | - | 14,191 | - | - |
| MSI-H | 2562 | 2.0% | 1432 | 11.8% | 1130 | 1.0% | < 0.001 |
| TMB ≥ 10 Mut/Mb1 | 16,709 | 16.8% | 3200 | 30.7% | 13,509 | 15.2% | < 0.001 |
| bTMB ≥ 10 Mut/Mb2 | 2832 | 16.5% | 215 | 18.3% | 2617 | 16.4% | 0.09 |
1Tissue CGP Only 2Liquid CGP Only w/ ctDNA Tumor Fraction (cTF) ≥ 1% A double dagger (‡) indicates a Significant Subcategory Difference. Statistical analysis was performed using Fisher’s Exact Tests or Chi-Squared Tests, as appropriate, and the p.adjust function in R was used for p-value multiple hypothesis corrections. bTMB Blood Tumor Mutational Burden, CGP Comprehensive Genomic Profiling, FDR False Discovery Rate, MSI-H Microsatellite Instability-High, PPGV Potential Pathogenic Germline Variant, TMB Tumor Mutational Burden.